Metabolic Therapy for Managing Diastolic Heart Failure


 Simon Sedej
Medical University of Graz, Graz, Austria

Wolfgang A. Linke, University of Münster, Münster, Germany
Adelino Leite-Moreira, Faculty of Medicine, University of Porto, Porto, Portugal
Guido Kroemer, French Institute of Health and Medical Research, INSERM, Paris, France
Jorge Alegre-Cebollada, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
Jörn Dengjel, University of Fribourg, Fribourg, Switzerland

Research focus:
Every fifth person aged over 65 years is at increased risk to develop diastolic heart failure essentially due to metabolic disorders, such as obesity or Diabetes Mellitus Type 2. No treatment has yet been shown to convincingly target and prevent diastolic heart failure. The MINOTAUR consortium will test whether caloric restriction-like acting compounds (also known as caloric restriction mimetics) prevent the development of diastolic dysfunction and improve diastolic function in a clinically relevant experimental model of diastolic heart failure, and taking into consideration gender aspect. Unraveling the molecular details of the disease can lead to nutrition–based personalized therapy (i.e., functional food-based nutritional regimes) as a novel and innovative protective and/or therapeutic approach that will likely result in fewer hospitalizations and promote healthy (cardiac) aging in future.